However, although long-term stabilization and partial tumor responses have been observed in PIK3CA-mutant cancers treated with PI3K inhibitors, the majority of PIK3CA- mutant cancers do not show substantial regression in clinical trials. This evidence concerns the gene PIK3CA and cancer.